{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:46:17Z","timestamp":1792413977862,"version":"4.4.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"suppl_9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.1093\/infdis\/jix402","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T11:07:31Z","timestamp":1505473651000},"page":"S801-S804","source":"Crossref","is-referenced-by-count":23,"title":["The World Health Organization\u2019s Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action"],"prefix":"10.1093","volume":"216","author":[{"given":"Silvia","family":"Bertagnolio","sequence":"first","affiliation":[{"name":"HIV Department, World Health Organization"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L","family":"Beanland","sequence":"additional","affiliation":[{"name":"Independent Public Health Specialist, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Jordan","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Doherty","sequence":"additional","affiliation":[{"name":"HIV Department, World Health Organization"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried","family":"Hirnschall","sequence":"additional","affiliation":[{"name":"HIV Department, World Health Organization"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"key\n\t\t\t\t20180328160810_CIT0001","volume-title":"Political Declaration on HIV and AIDS: On the Fast Track to Accelerate the Fight Against HIV and to End the AIDS Epidemic by 2030","author":"United Nations General Assembly","year":"2016"},{"key":"key\n\t\t\t\t20180328160810_CIT0002","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS\u2013Associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328160810_CIT0003","author":"UNAIDS"},{"key":"key\n\t\t\t\t20180328160810_CIT0004","volume-title":"Global AIDS Monitoring","author":"UNAIDS, WHO","year":"2017"},{"key":"key\n\t\t\t\t20180328160810_CIT0005","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","article-title":"Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey","volume":"3","author":"\u00c1vila-R\u00edos","year":"2016","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180328160810_CIT0006","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1089\/aid.2006.0310","article-title":"Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz","volume":"23","author":"Borroto-Esoda","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328160810_CIT0007","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAI.0000000000000942","article-title":"Response to therapy in antiretroviral therapy-naive patients with isolated nonnucleoside reverse transcriptase inhibitor-associated transmitted drug resistance","volume":"72","author":"Clutter","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328160810_CIT0008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000000509","article-title":"Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia","volume":"68","author":"Hong","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328160810_CIT0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0b013e31817ae5c0","article-title":"Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study","volume":"48","author":"Bannister","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328160810_CIT0010","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1177\/135965350701200814","article-title":"Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network","volume":"12","author":"Chaix","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180328160810_CIT0011","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328160810_CIT0012","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkx188","article-title":"Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children","author":"Kityo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328160810_CIT0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0000000000000108","article-title":"Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia","volume":"66","author":"Phanuphak","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180328160810_CIT0014","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1089\/aid.2014.0043","article-title":"Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda","volume":"30","author":"Lee","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20180328160810_CIT0015","doi-asserted-by":"crossref","first-page":"e95956","DOI":"10.1371\/journal.pone.0095956","article-title":"First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study","volume":"9","author":"Zu Knyphausen","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180328160810_CIT0016","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa0906626","article-title":"Antiretroviral therapies in women after single-dose nevirapine exposure","volume":"363","author":"Lockman","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328160810_CIT0017","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000001575","article-title":"High rates of baseline drug resistance and virologic failure among ART na\u00efve HIV-infected children in Mali","author":"Crowell","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180328160810_CIT0018","doi-asserted-by":"crossref","first-page":"21140","DOI":"10.7448\/IAS.19.1.21140","article-title":"High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children","volume":"19","author":"Boerma","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180328160810_CIT0019","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/cid\/civ102","article-title":"Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial","volume":"60","author":"Kantor","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328160810_CIT0020","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/528802","article-title":"Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects","volume":"197","author":"Kuritzkes","year":"2008","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180328160810_CIT0021","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180328160810_CIT0022","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1097\/QAD.0b013e3283636179","article-title":"The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1\u2013infected adults","volume":"27","author":"Mackie","year":"2013","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180328160810_CIT0023","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/tmi.12563","article-title":"Virological efficacy with first-line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression","volume":"20","author":"Shet","year":"2015","journal-title":"Trop Med Int Health"},{"key":"key\n\t\t\t\t20180328160810_CIT0024","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/cid\/civ656","article-title":"Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa","volume":"61","author":"Boender","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180328160810_CIT0025","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jac\/dkr601","article-title":"Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan","volume":"67","author":"Lai","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180328160810_CIT0026","volume-title":"Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance","author":"World Health Organization","year":"2017"},{"key":"key\n\t\t\t\t20180328160810_CIT0027","volume-title":"HIV Drug Resistance Report 2017","author":"World Health Organization","year":"2017"},{"key":"key\n\t\t\t\t20180328160810_CIT0028","volume-title":"Global Action Plan on HIV Drug Resistance, 2017\u20132021","author":"World Health Organization","year":"2017"},{"key":"key\n\t\t\t\t20180328160810_CIT0029","volume-title":"Global Action Plan on Antimicrobial Resistance","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20180328160810_CIT0030","volume-title":"Global Action Plan on Antimicrobial Resistance","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20180328160810_CIT0031","volume-title":"Malawi Population-Based HIV Impact Assessment","author":"PHIA Project"},{"key":"key\n\t\t\t\t20180328160810_CIT0032","volume-title":"Zimbabwe Population-Based HIV Impact Assessment","author":"PHIA Project"},{"key":"key\n\t\t\t\t20180328160810_CIT0033","volume-title":"Swaziland HIV Incidence Measurement Survey 2: A Population-Based HIV Impact Assessment. Preliminary findings","author":"PHIA Project"},{"key":"key\n\t\t\t\t20180328160810_CIT0034","volume-title":"Zimbabwe Population-Based HIV Impact Assessment","author":"PHIA Project"},{"key":"key\n\t\t\t\t20180328160810_CIT0035","volume-title":"Consolidated Strategic Information Guidelines for HIV in the Health Sector: HIV Strategic Information for Impact","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20180328160810_CIT0036","volume-title":"HIV Drug Resistance Surveillance Guidance: 2015 Update","author":"World Health Organization","year":"2015"},{"key":"key\n\t\t\t\t20180328160810_CIT0037","volume-title":"Global report on early warning indicators of HIV drug resistance: technical report","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20180328160810_CIT0038","volume-title":"Consolidated Guidelines on Person-Centred HIV Patient Monitoring and Case Surveillance","author":"World Health Organization","year":"2017"},{"key":"key\n\t\t\t\t20180328160810_CIT0039","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hiv.12435","article-title":"An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition","volume":"18","author":"St-Jean","year":"2017","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180328160810_CIT0040","volume-title":"WHO HIV Drug Resistance Report 2012","author":"World Health Organization","year":"2012"},{"key":"key\n\t\t\t\t20180328160810_CIT0041","volume-title":"HIV Drug Resistance Laboratory Strategy","author":"World Health Organization"},{"key":"key\n\t\t\t\t20180328160810_CIT0042","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMc1611639","article-title":"Multidrug-resistant HIV-1 infection despite preexposure prophylaxis","volume":"376","author":"Knox","year":"2017","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/suppl_9\/S801\/24264721\/jix402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:22:51Z","timestamp":1750879371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/suppl_9\/S801\/4494144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":42,"journal-issue":{"issue":"suppl_9","published-online":{"date-parts":[[2017,10,13]]},"published-print":{"date-parts":[[2017,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix402","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11,15]]},"published":{"date-parts":[[2017,10,13]]}}}